BIOGEN INC.
Close on Oct 19, 2026
- Market cap
- $34.72B
- P/E (TTM)
- 41.3
- Dividend yield
- –
Earnings
Next report expected Oct 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 1, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 6, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 14, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 14, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 7, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $2.40B | $1.64 | $3.02 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 12, 2025 | Before market open | $2.50B | $1.83 | $3.44 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $2.50B | $2.66 | $4.08 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | $2.50B | $4.00 | $5.28 |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 24, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 13, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on May 1, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Non-GAAP diluted EPSnon-GAAP | full year 2025 | $14.50 to $15.50 | Lowered |
| combined Non-GAAP R&D expense and Non-GAAP SG&A expensenon-GAAP | 2025 | $3.90B | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Biogen filed with the SEC
Cambridge, Mass. – July 29, 2026
Results of operations · EX-99.1 to Form 8-K
Biogen Completes Acquisition of Apellis Pharmaceuticals
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Cambridge, Mass. – April 29, 2026
Results of operations · EX-99.1 to Form 8-K
This TENDER AND SUPPORT AGREEMENT (this “ Agreement ”), dated as of March 31, 2026, is by and among Biogen
Material agreement · Other events · EX-99.1 to Form 8-K
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and
Material agreement · Other events · EX-99.2 to Form 8-K
March 31, 2026 BIOGEN PROPOSED ACQUISITION OF APELLIS INVESTOR WEBCAST
Material agreement · Other events · EX-99.3 to Form 8-K
Cambridge, Mass. – February 6, 2026
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – October 30, 2025
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – July 31, 2025
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – May 1, 2025
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – Feb. 12, 2025
Results of operations · EX-99.1 to Form 8-K
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cambridge, Mass. – October 30, 2024
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – Aug. 1, 2024
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – Apr. 24, 2024
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – Feb. 13, 2024
Results of operations · EX-99.1 to Form 8-K
Cambridge, Mass. – Nov. 8, 2023
Results of operations · EX-99.1 to Form 8-K
Biogen Completes Acquisition of Reata Pharmaceuticals
Other events · EX-99.1 to Form 8-K
DRAFT SUBJECT TO FURTHER REVIEW
Other events · EX-99.1 to Form 8-K
Investor Webcast July 28, 2023
Other events · EX-99.2 to Form 8-K
Cambridge, Mass. – July 25, 2023
Results of operations · EX-99.1 to Form 8-K
Strong progress toward three potential launches in 2023;
Results of operations · EX-99.1 to Form 8-K
Biogen advances significant potential growth drivers; Company reports full year 2022 results and provides full year 2023 guidance
Results of operations · EX-99.1 to Form 8-K
Biogen Names Christopher Viehbacher President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Biogen Reports Third Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Biogen Reports Second Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K/A
Biogen Reports Second Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
BIOGEN REPORTS FIRST QUARTER 2022 RESULTS
Results of operations · Executive or director change · EX-99.1 to Form 8-K
BIOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOGEN REPORTS THIRD QUARTER 2021 RESULTS
Results of operations · EX-99.1 to Form 8-K